Candel Therapeutics (CADL) Enterprise Value (2020 - 2023)
Historic Enterprise Value for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to -$43.0 million.
- Candel Therapeutics' Enterprise Value rose 4428.83% to -$43.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$43.0 million, marking a year-over-year increase of 4428.83%. This contributed to the annual value of -$70.1 million for FY2022, which is 1522.71% up from last year.
- Candel Therapeutics' Enterprise Value amounted to -$43.0 million in Q3 2023, which was up 4428.83% from -$51.9 million recorded in Q2 2023.
- Candel Therapeutics' Enterprise Value's 5-year high stood at -$24.3 million during Q2 2021, with a 5-year trough of -$94.3 million in Q1 2022.
- For the 4-year period, Candel Therapeutics' Enterprise Value averaged around -$64.8 million, with its median value being -$70.1 million (2022).
- As far as peak fluctuations go, Candel Therapeutics' Enterprise Value plummeted by 25689.26% in 2022, and later surged by 4428.83% in 2023.
- Candel Therapeutics' Enterprise Value (Quarter) stood at -$35.1 million in 2020, then crashed by 135.76% to -$82.6 million in 2021, then increased by 15.23% to -$70.1 million in 2022, then skyrocketed by 38.62% to -$43.0 million in 2023.
- Its Enterprise Value stands at -$43.0 million for Q3 2023, versus -$51.9 million for Q2 2023 and -$59.3 million for Q1 2023.